Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
Go back to Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy| (NASDAQ: SLDB) | Delayed: 7.14 -0.08 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.22 | 52 Week High | $ | |||
| Open | $7.26 | 52 Week Low | $ | |||
| Day High | $7.45 | P/E | N/A | |||
| Day Low | $7.12 | EPS | $ | |||
| Volume | 1,664,864 | |||||
